LAUSR

Abstract Context Parkinson's disease is a common chronic neurodegenerative disease characterized by massive loss of dopaminergic neurons in the substantia nigra. Neuroinflammation has been shown to play an important role in the pathogenesis of neurodegenerative diseases such as Parkinson’s disease. The role of immune tolerance in neuroinflammation and neurodegenerative diseases induced by peripheral factors is unclear. Objective This study established a model of endotoxin tolerance to explore the protective effect of endotoxin tolerance on Parkinson-like changes induced by repeated peripheral injections of high-dose LPS, and to explore its inflammatory mechanism. Materials and methods In this study, mice were injected intraperitoneally with low dose (0.5 mg/kg) LPS for 4 days to induce endotoxin tolerance (ET). Then, high-dose (1 mg/kg) LPS was injected continuously intraperitoneally for 4 days to induce Parkinson-like changes. Cytokines were detected by enzyme-linked immunosorbent assay (ELISA) and quantitative real-time polymerase chain reaction (qRT-PCR). Activation of microglial cells was detected by protein expression of CD68 and ionized calcium binding adapter molecule 1(Iba-1) by Western blotting and immunofluorescence. Hematoxylin and eosin staining and expression of tyrosine hydroxylase (TH) and dopamine (DA) were used to assess dopaminergic neuronal injury. The open field test and muscle tension test were used to assess behavioral disorders. Results As expected, compared with non-ET animals, ET preconditioning significantly reduced the production of inflammatory cytokines in the substantia nigra, inhibited microglial activation, and alleviated the pathological changes of dopaminergic neurons. Conclusions ET may be a promising intervention method for neurodegenerative diseases. Highlights ET was successfully induced by continuous low-dose intraperitoneal LPS injection in mice. ET pretreatment inhibited neuroinflammation in the SN induced by continuous peripheral high doses of LPS. ET pretreatment inhibited continuous peripheral high-dose LPS injection-induced microglial activation in the SN. ET pretreatment decreased LPS-induced functional impairment of dopaminergic neurons. ET reversed the morphological changes of dopaminergic neurons induced by peripheral high-dose LPS. ET pretreatment improved continuous peripheral high-dose LPS injection-induced behavioral impairment.